A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (NCT04691804)
SHR3162-III-305
This trial is No longer recruiting
Registration number NCT04691804
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Mark Voskoboynik
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR